Opportunities Ripe For Pharmaceutical Companies in Ghana and Nigeria
Strong business opportunities exist for big pharmaceutical and generic pharmaceutical companies in Ghana and Nigeria. This is of no surprise as the tropical climate of Africa makes the continent a hotbed for infectious diseases, particularly malaria, tuberculosis and AIDS. Outbreaks of polio, meningitis, cholera, pandemic influenza, yellow fever, measles, hepatitis and tetanus are also frequent. The rising adoption of a Western diet and sedentary lifestyle is also causing a paradigm shift in the burden of illness towards non-communicable diseases (NCDs).
New analysis from Frost & Sullivan, Pharmaceutical Industry in Ghana and Nigeria, finds that the market earned revenues of $1.63 billion in 2013 and estimates this to reach $3.12 billion in 2018 at a compound annual growth rate of 13.9%. The study covers branded, generic and over-the-counter pharmaceuticals.
“Increased economic wealth and healthcare investment, changing lifestyle patterns, and improved awareness on the importance of health status among West Africans will take the African pharmaceutical industry to $40 billion by 2018,” said Frost & Sullivan Healthcare Senior Research Analyst Aiswariya Chidambaram. “A significant portion of the industry’s expected value will come from Ghana and Nigeria.”
The demand for chronic prescription drugs will persist as NCDs such as cardiovascular disease, cancer, diabetes and respiratory disease are expected to witness high growth rates throughout the forecast period. Pharmaceutical companies would do well to develop efficacious drugs to treat NCDs as the World Health Organisation predicts that the proportional contribution of these diseases to the healthcare burden in Africa will rise by 21% through 2030.
However, pharma companies might find it challenging to exploit the upward trend in NCDs owing to the weak regulatory policies in Ghana and Nigeria, which delay the drug approval process and impose limitations on market access. The lack of tiered pricing levels and other complexities associated with public sector tendering in Ghana and Nigeria also make it difficult for multinational companies to compete, thereby impeding the growth of innovative, high-quality products.
In the private market, fragmented payer channels between donors, private insurance payers and employers, along with limited ability of patients to pay out-of-pocket for treatments are restricting access to medicines. In the rural market, the insufficient number of pharmacies and private clinics to distribute medicines is leading to the circulation of counterfeit drugs, limiting the scope of the legitimate pharmaceutical industry.
To penetrate the market, foreign pharmaceutical companies must bolster their distribution channels by entering strategic partnerships with local, trustworthy stakeholders. They will also need to address the loopholes in the supply chain and distribution channels to ensure product availability and prevent the distribution of counterfeit drugs.
“Investing in the technical training of distributors and pharmacists, as well as product-specific initiatives such as using bar-codes and holograms to track counterfeits, can help minimise drug trafficking and enhance brand image,” pointed out Chidambaram. “Adopting effective distribution models that optimise product price without reducing margins will also be crucial.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance